Following a positive interim analysis showing that fractional flow-reserve-guided PCI was superior to optimal medical treatment, an independent Data and Safety Monitoring Board (DSMB) has recommended that patient enrollment in the ongoing FAME II trial be stopped. The news was announced by the trial sponsor, St. Jude Medical. FAME II (Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Plus Optimal…
Recent Comments